ijms-logo

Journal Browser

Journal Browser

Gynecologic Oncology: Tumor Microenvironment and Novel Therapeutics

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: closed (30 November 2025) | Viewed by 695

Special Issue Editor

Special Issue Information

Dear Colleagues,

The tumor microenvironment (TME)—composed of blood vessels, immune cells, stem cells, fibroblasts, and the extracellular matrix (ECM)—has increasingly implicated as a key controlling factor in tumor progression and therapy resistance. The primary microenvironment for ovarian cancer cells at the metastatic site is the peritoneum, a single layer of epithelial cells covering the abdominal cavity and its organs. Implantation and invasion occur within a tumor–host interface where cancer and peritoneal cells exchange proteins and peptides, which modify the local ECM and promote metastasis. Malignant ascites is a unique TME present in more than one-third of ovarian cancer patients at initial diagnosis and in almost all cases of relapse. Ascites contain multicellular spheroids that are enriched in cancer stem-like cells and contribute to ovarian cancer metastasis and chemotherapy resistance. The ascites fluid also provides an immunosuppressive peritoneal TME that helps cancer cells evade immune surveillance and promotes tumor growth and metastasis. This research topic aims to generate a discussion around the current research and understanding of cancer cell-TME interactions and novel therapeutic strategies targeting the TME. We encourage and invite ovarian cancer and other gynecological cancer researchers to contribute original research articles or review articles.

Dr. Carmela Ricciardelli
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • tumor microenvironment
  • peritoneal-cancer cell interactions
  • extracellular matrix
  • ascites
  • immune cells
  • cancer-associated fibroblasts
  • immunotherapy
  • novel therapeutic targets

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

20 pages, 1788 KB  
Review
Normalizing the Tumor Microenvironment: A New Frontier in Ovarian Cancer Therapy
by Adam P. Jones, Yanxia Zhao, Bo R. Rueda, Oladapo O. Yeku and Lei Xu
Int. J. Mol. Sci. 2026, 27(2), 939; https://doi.org/10.3390/ijms27020939 - 17 Jan 2026
Viewed by 428
Abstract
Ovarian cancer is one of the deadliest gynecological malignancies, where most patients become clinically symptomatic at advanced stages of disease due to the lack of effective diagnostic screening. Despite recent advances in surgical resection and chemotherapy, recurrent ovarian cancer remains largely refractory to [...] Read more.
Ovarian cancer is one of the deadliest gynecological malignancies, where most patients become clinically symptomatic at advanced stages of disease due to the lack of effective diagnostic screening. Despite recent advances in surgical resection and chemotherapy, recurrent ovarian cancer remains largely refractory to treatment, resulting in poor prognosis. The ovarian cancer tumor microenvironment (TME) is highly abnormal and presents a significant barrier to successful therapy. A combination of abnormal vasculature, desmoplastic extracellular matrix, and aberrantly activated hypoxic and immune-suppressive pathways culminates in promoting tumor growth, dissemination, chemoresistance, and immunosuppression. Whilst immune checkpoint inhibitors have shown success in other cancers, their application in ovarian cancer, particularly at advanced stages, remains limited. In this review, we discussed the application of tumor extracellular matrix normalizing therapies in preclinical models of advanced ovarian cancer, and their synergistic benefit to chemotherapy and immunotherapy. Collectively, these insights underscore TME normalization as a promising therapeutic strategy with the potential to improve ovarian cancer management. Full article
(This article belongs to the Special Issue Gynecologic Oncology: Tumor Microenvironment and Novel Therapeutics)
Show Figures

Figure 1

Back to TopTop